Gene-guided Warfarin for Anticoagulation Therapy in Patients With Acute Ischemic Stroke
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- Stroke recurrence rate, compliance rate of INR value
研究概览
简要总结
This study will explore the effect of warfarin gene polymorphism on the effectiveness and safety of anticoagulant therapy in patients with acute ischemic stroke, and clarify the correlation between genetic testing and compliance rate of INR value. It will illustrate the significance of gene-guided warfarin for administered dose to anticoagulation therapy in patients with acute ischemic stroke. Then it will establish and verify a warfarin stable dose prediction model suitable for such patients, and provide basis for the personalized medication regimen of warfarin in patients with acute ischemic stroke.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with acute ischemic stroke aged ≥18 years (cardiogenic cerebral embolism patients)
- •Clinicians judge that long-term oral anticoagulation with warfarin is required
- •No anticoagulation treatment in the past 10 days
- •Agree to participate in this project
排除标准
- •Patients who had a tendency to bleed when taking warfarin
- •High-risk groups using warfarin anticoagulation
研究组 & 干预措施
Gene-guided Warfarin
干预措施: Gene detection (CYP2C9*3, VKORC1) (Device)
Gene-guided Warfarin
干预措施: Warfarin Sodium (Drug)
Routine use
干预措施: Warfarin Sodium (Drug)
结局指标
主要结局
Stroke recurrence rate, compliance rate of INR value
时间窗: 12 months
Evaluation and analysis of the stroke recurrence rate and compliance rate of INR value at 12 months after treatment
次要结局
未报告次要终点